)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Kolon TissueGene
Kolon TissueGene (950160) investor relations material
Kolon TissueGene Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Focus on cell and gene therapy platform (TG-C) for osteoarthritis, with U.S. Phase 3 clinical trials completed for knee OA and ongoing for other indications.
Revenue primarily from B2B technology licensing and distribution of health/beauty products; no commercial sales of TG-C yet.
Significant R&D investment, with pipeline expansion into hip OA, degenerative disc disease, and potential animal health applications.
Multiple legal proceedings related to past product issues and shareholder claims.
Financial highlights
2026 H1 revenue: $1.51M (down from $3.63M in 2025 H1); operating loss: $(8.47)M (improved from $(15.70)M in 2025 H1).
Net loss for 2026 H1: $(34.71)M; basic EPS: $(2.06).
Cash and equivalents: $43.8M; convertible bonds outstanding: $37.3M.
R&D expenses remain high, exceeding 2,100% of revenue.
Outlook and guidance
U.S. Phase 3 TG-C 15302 topline data released post-period; primary endpoint not met, further analysis ongoing.
TG-C 12301 study and follow-up analysis to inform future regulatory and commercialization strategy.
Pipeline expansion into hip OA and DDD continues, with additional clinical trials planned.
Strategy after TG-C 15302 missed primary endpoint
Plan for current convertible bond liabilities
Preparation status for DDD Phase 1 trial in 2026
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kolon TissueGene
- TG-C advances toward FDA approval with strong clinical data and global commercialization plans.950160
Corporate presentation - Heavy R&D spending drives losses as Phase 3 knee OA trial completes and pipeline expands.950160Q3 2024
- Revenue up 31% but net loss deepens; Phase 3 knee OA trials completed, BLA submission ahead.950160Q4 2024
- Losses narrowed as Phase 3 TG-C trials completed dosing; focus remains on FDA approval.950160Q2 2024
- Phase 3 dosing for TG-C completed; losses persist, but cash position strengthened.950160Q1 2025
- 2025 net loss widened to $135.4M as TG-C phase 3 trials completed dosing; BLA filing planned.950160Q4 2025
- H1 2025 saw $1.83M revenue, $(44.2)M net loss, and high R&D costs amid pivotal TG-C trials.950160Q2 2025
- Heavy R&D spending and high leverage persist as FDA approval for TG-C becomes pivotal.950160Q1 2026
- TG-C Phase 3 completed; revenue down, net loss $(48.6)M, strong cash after capital raises.950160Q3 2025
Next Kolon TissueGene earnings date
Q3 202613 Nov, 2026
Kolon TissueGene
Next Kolon TissueGene earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage